NCT05586321View on ClinicalTrials.gov

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

October 21, 2025

Study Completion Date

October 21, 2025

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

GEN1056

GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.

Trial Locations (7)

Unknown

ARENSIA Exploratory Medicine LLC, Tbilisi

ARENSIA Exploratory Medicine Phase I Unit, Chisinau

Hospital Universitari Vall d'Hebron, Barcelona

Centro Integral Oncologico Clara Campal, Madrid

Hospital Universitario Fundacion Jimenez Diaz, Madrid

MD Anderson Cancer Centre, Madrid

Clinica Universidad de Navarra, Pamplona

Sponsors

Lead Sponsor

Genmab

Collaborators (1)

BioNTech SE
All Listed Sponsors
collaborator

BioNTech SE

INDUSTRY

lead

Genmab

INDUSTRY

NCT05586321 - Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter